Association between the cumulative exposure to atherogenic index of plasma and risk of cardiometabolic diseases: a prospective cohort study

作者：Meixiao Wang, Shihe Liu, Luqing Liu, Xinran Wen, Yicheng Liao, Hong‐Min Liu, Shouling Wu, Yuntao Wu · 发表于：Endocrine · 年份：2025 · DOI：10.1007/s12020-025-04197-9 · 被引用次数：3 · 研究领域：Inflammatory Biomarkers in Disease Prognosis、Diabetes, Cardiovascular Risks, and Lipoproteins、Adipokines, Inflammation, and Metabolic Diseases

PURPOSE: Plasma atherogenic index is a major risk factor for cardiac metabolic disease, but the long-term effect of high cumAIP on the risk of CMD development is unclear. Therefore, we aimed to determine the effect of cumulative plasma atherogenic index exposure on cardiac metabolic disease. METHODS: A total of 44,603 subjects who participated in the Kailuan Study health examination in 2006, 2008 and 2010, had complete blood lipid data, and had no previous history of CMD or cancer were selected. The cumulative AIP index was calculated as a weighted sum (value × time) of the average AIP index during each time interval. The population was divided into four groups according to the cumAIP quartile level. Cox proportional hazards regression model and restricted cubic spline regression model were used to further analyze the effect of cumAIP on the risk of CMD. Due to the competing risk of death, the traditional Cox model may cause bias on the risk of CMD. Therefore, death was regarded as a competing event, and the Fine-Gray model was used to analyze the difference in the risk of CMD in different cumAIP groups. RESULTS: During a mean follow-up period of (9.79 ± 2.60) years, 7674 (17.21%) of 44603 participants developed CMD. After adjusting for potential confounding factors, Cox regression analysis showed that compared with group Q1, the risk of CMD in group Q2, Q3, and Q4 increased by 26% (HR = 1.26, 95%CI: 1.17-1.36) and 44% (HR = 1.44, 95%CI: 1.17-1.36), respectively. 95%CI: 1.34-...